Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against DraftKings Inc. f/k/a Diamond Eagle Acquisition Corp. ( DEAC , DraftKings , or the Company ) (NASDAQ: DKNG) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-05739, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired DraftKings securities between December 23, 2019 and June 15, 2021, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Orphazyme A/S ( Orphazyme or the Company ) (NASDAQ: ORPH) and certain of its officers and directors. The class action, filed in the United States District Court for the Northern District of Illinois, Eastern Division, and docketed under 21-cv-03640, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired: (a) Orphazyme American depositary shares ( ADSs ) pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company s initial public offering conducted on or about September 29, 2020 (the IPO or Offering ); and/or (b) Orphazyme securities between September 29, 2020 and June 18, 2021, both dates inclusive (the Class Period ). Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the Securities
The Limits of HCQIA Immunity: Disclosure of Information Outside of Professional Review Bodies and Falsity of Information Tuesday, August 3, 2021
The United States District Court for the Western District of Washington’s decision interpreting the Health Care Quality Improvement Act, 42 U.S.C. § 11101,
et seq.
, (“HCQIA”), highlights specific requirements for immunity from damages under HCQIA, specifically limiting dissemination of peer review information to professional review bodies and avoiding information that is false and known to be false.[1]
Hospital Removes Physician as Chair of Neurosurgery After Receipt of Numerous Complaints
Defendant, Dr. Charles Cobbs, originally sent a letter on November 4, 2016, to the Swedish Medical Center (“Hospital”) Chief Executive Officer (“CEO”) and two other Hospital administrators regarding Dr. Johnny Delashaw, Jr., a neurosurgeon and the Chair of Neurosurgery and Spine at the Swedish Neuroscience Institute (“S
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Companies, Inc. ( Rocket or the Company ) (NYSE: RKT) and certain of its officers. The class action, filed in the United States District Court for the Eastern District of Michigan, Southern Division, and docketed under 21-cv-11618, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Rocket Class A common stock between February 25, 2021 and May 5, 2021, both dates inclusive (the Class Period ), seeking to pursue remedies under the Securities Exchange Act of 1934 (the Exchange Act ) against Rocket and certain of the Company s senior officers.
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against CarLotz, Inc. ( CarLotz or the Company ) (NASDAQ: LOTZ) (NASDAQ: LOTZW) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-06191, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired CarLotz securities between December 30, 2020 and May 25, 2021, inclusive (the Class Period ).Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the Exchange Act ).